Home

Jubilant Pharmova Ltd PE Ratio

Image

Jubilant Pharmova Ltd

NSE: JUBLPHARMA

PE

45.9

Last updated on: Apr 03, 2025

Key Highlights

  • The P/E Ratio of Jubilant Pharmova Ltd is 45.9 as of 03 Apr 9.00 AM .
  • The P/E Ratio of Jubilant Pharmova Ltd changed from 4.4 on March 2020 to 116.5 on March 2024 . This represents a CAGR of 92.56% over 5 years.
  • The Latest Trading Price of Jubilant Pharmova Ltd is ₹ 971.65 as of 03 Apr 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.2. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.1 in 2024.

Historical P/E Ratio of Jubilant Pharmova Ltd

No data available

Company Fundamentals for Jubilant Pharmova Ltd

Image

Jubilant Pharmova Ltd

NSE: JUBLPHARMA

Share Price

₹ 971.65

62.05 (6.82%)

stock direction

Last updated on: Apr 03, 2025

Market Price of Jubilant Pharmova Ltd

1M

1Y

3Y

5Y

Monitoring Jubilant Pharmova Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
03 Apr 2025971.65
02 Apr 2025909.6
01 Apr 2025914.4
28 Mar 2025892.7
27 Mar 2025891.75
26 Mar 2025859.55
25 Mar 2025870.55
24 Mar 2025895.7
21 Mar 2025902.55
20 Mar 2025898.55

SWOT Analysis Of Jubilant Pharmova Ltd

Strength

3

che

Weakness

2

che

Opportunity

0

che

Threats

1

che

BlinkX Score for Jubilant Pharmova Ltd

Asset Value vs Market Value of Jubilant Pharmova Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Jubilant Pharmova Ltd15478
Sun Pharmaceutical Industries Ltd424706
Divis Laboratories Ltd152946
Cipla Ltd120751
Torrent Pharmaceuticals Ltd109983
Mankind Pharma Ltd100168

PE Ratio of Jubilant Pharmova Ltd Explained

15478

Market cap

627

Earnings

45.9X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Jubilant Pharmova Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Jubilant Pharmova Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Jubilant Pharmova Ltd

No data available

* All values are in %

About Jubilant Pharmova Ltd

  • Jubilant Pharmova Limited, (Formerly known as Jubilant Life Sciences Limited), is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
  • The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
  • The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA. The contract research and development segment provides drug discovery and development services as well as clinical data software and service solutions.

Jubilant Pharmova Ltd News Hub

Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories

Jubilant Biosys Innovative Research Services,, Singapore (JBIRSPL), subsidiary of Jubilant Biosys (J

Read more

16 Aug 24

Volumes soar at Jubilant Pharmova Ltd counter

Firstsource Solutions Ltd, Adani Energy Solutions Ltd, Sapphire Foods India Ltd, Lloyds Metals & Ene

Read more

01 Aug 24

Volumes soar at Jubilant Pharmova Ltd counter

Alembic Pharmaceuticals Ltd, Doms Industries Ltd, EPL Ltd, Anand Rathi Wealth Ltd are among the othe

Read more

09 Sept 24

Jubilant Pharmova Ltd leads gainers in 'A' group

Morepen Laboratories Ltd, La Opala RG Ltd, AGI Greenpac Ltd and Gujarat Alkalies & Chemicals Ltd are

Read more

09 Sept 24

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Jubilant Pharmova Ltd

What is the current PE Ratio of Jubilant Pharmova Ltd?

The Current PE Ratio of Jubilant Pharmova Ltd is 45.92 as on 3 Apr 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 3 Apr 2025.

What was the PE Ratio of Jubilant Pharmova Ltd last year?

The PE Ratio of Jubilant Pharmova Ltd was 0.0 last year, now the PE ratio is 45.92, showing a year-on-year growth of -%.

What does the PE Ratio of Jubilant Pharmova Ltd indicate about its stock?

The PE Ratio of Jubilant Pharmova Ltd is 45.92. This ratio indicates that investors are willing to pay 45.92 times the earnings per share for each share of Jubilant Pharmova Ltd.

What is the PE Ratio Growth of Jubilant Pharmova Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Jubilant Pharmova Ltd grew by -% whereas, the EPS ratio grew by -1.5.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions